

# Elvire Pons-Tostivint

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9325474/publications.pdf>

Version: 2024-02-01

5  
papers

115  
citations

1683934

5  
h-index

2053595

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

110  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 <sup>hi</sup> non-small cell lung cancer patients treated with first-line pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1747-1756.	2.0	5
2	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. <i>Current Oncology</i> , 2022, 29, 3748-3758.	0.9	7
3	STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. <i>Cells</i> , 2021, 10, 3129.	1.8	30
4	Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. <i>Radiotherapy and Oncology</i> , 2020, 145, 109-116.	0.3	26
5	Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 356-365.	0.7	47